Insider Selling: Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Insider Sells 4,000 Shares of Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $27.70, for a total value of $110,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Thomas Gad also recently made the following trade(s):

  • On Monday, August 5th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $21.78, for a total value of $87,120.00.
  • On Monday, July 22nd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.54, for a total value of $90,160.00.
  • On Monday, July 8th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.40, for a total value of $89,600.00.
  • On Monday, June 24th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $21.77, for a total value of $87,080.00.
  • On Monday, June 10th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.79, for a total value of $91,160.00.
  • On Monday, June 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.03, for a total value of $80,120.00.
  • On Tuesday, May 28th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.21, for a total value of $121,260.00.

Shares of Y-mAbs Therapeutics stock traded down $0.68 during trading on Tuesday, hitting $27.21. 193,014 shares of the company were exchanged, compared to its average volume of 114,184. The firm has a market capitalization of $954.00 million and a P/E ratio of -18.11. Y-mAbs Therapeutics, Inc has a 1-year low of $15.17 and a 1-year high of $31.00. The firm’s fifty day moving average price is $23.44 and its 200 day moving average price is $22.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.04 and a quick ratio of 9.04.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.05). As a group, equities research analysts anticipate that Y-mAbs Therapeutics, Inc will post -2.04 earnings per share for the current year.

Several equities analysts have recently issued reports on the company. Cowen restated a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Monday, July 1st. Zacks Investment Research upgraded Y-mAbs Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Saturday, August 3rd. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price (up from $36.00) on shares of Y-mAbs Therapeutics in a research report on Monday, June 10th. Six analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $31.40.

Several large investors have recently added to or reduced their stakes in YMAB. BNP Paribas Arbitrage SA acquired a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $38,000. Bank of Montreal Can bought a new stake in shares of Y-mAbs Therapeutics during the 2nd quarter valued at $39,000. TD Asset Management Inc. lifted its position in shares of Y-mAbs Therapeutics by 11.5% during the 2nd quarter. TD Asset Management Inc. now owns 25,453 shares of the company’s stock valued at $582,000 after acquiring an additional 2,624 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Y-mAbs Therapeutics by 10.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 33,189 shares of the company’s stock valued at $739,000 after acquiring an additional 3,115 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Y-mAbs Therapeutics by 3,056.5% during the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock valued at $122,000 after acquiring an additional 5,838 shares during the period. Institutional investors and hedge funds own 29.51% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.